USMLE Prep - Medical Reference Library

Bullous Pemphigoid - Acute Flare and ED Management

System: Dermatology • Reviewed: Aug 31, 2025 • Step 1Step 2Step 3

Synopsis:

Tense pruritic bullae in older adults; avoid debridement, treat secondary infection, start high potency topical corticosteroid for localized disease or systemic prednisone when extensive, and ensure dermatology follow up.

Key Points

  • Stabilize ABCs; begin targeted evaluation without delaying life-saving therapy.
  • Use system-specific risk tools to guide testing and disposition.
  • Order high-yield tests first; escalate imaging when indicated.
  • Start evidence-based initial therapy and reassess frequently.

Algorithm

  1. Primary survey and vitals; IV access and monitors.
  2. Focused history/physical; identify red flags and likely etiologies.
  3. Order system-appropriate labs and imaging (see Investigations).
  4. Initiate guideline-based empiric therapy (see Pharmacology).
  5. Reassess response; arrange consultation and definitive management.

Clinical Synopsis & Reasoning

For Bullous Pemphigoid Acute Flare Ed Management, frame the differential by acuity and pathophysiology, then align diagnostics to the leading hypotheses. Prioritize stabilization while obtaining high‑yield studies such as CBC (Baseline hematology), BMP (Electrolytes/renal). Incorporate bedside imaging and targeted labs to define severity and identify complications; synthesize results with clinical trajectory to refine the working diagnosis and disposition needs.


Treatment Strategy & Disposition

Initiate disease‑directed therapy alongside supportive care, titrating to objective response. Pharmacologic options commonly include Analgesia/Antipyretics. Use validated frameworks (e.g., When to admit) to guide escalation and site of care. Address precipitating factors, de‑escalate empiric therapies with data, and arrange follow‑up for monitoring and risk‑factor modification; admit patients with instability, high risk of deterioration, or needs for close monitoring.


Epidemiology / Risk Factors

  • Risk factors vary by condition and patient profile

Investigations

TestRole / RationaleTypical FindingsNotes
CBCBaseline hematologyAbnormal counts
BMPElectrolytes/renalDerangements

When to admit

ScenarioReason
Extensive skin loss or dehydrationNeed for fluids, dressings, and monitoring
Widespread superinfection or sepsis riskIV antibiotics and wound care
Frailty or limited self careSafe dressing changes and therapy

Pharmacology

MedicationMechanismOnsetRole in TherapyLimitations
AcetaminophenAnalgesic/antipyreticHoursSymptom control as appropriateHepatotoxicity (overdose)
Ondansetron5-HT3 antagonismMinutesAntiemesis if neededQT prolongation

Prognosis / Complications

  • Prognosis depends on severity, comorbidities, and timeliness of care

Patient Education / Counseling

  • Explain red flags and when to seek emergent care.
  • Reinforce medication adherence and follow-up plan.

Notes

Monitor glucose and infection risk with systemic steroids. Consider steroid sparing options with dermatology such as doxycycline with nicotinamide or immunosuppressants when appropriate.


References

  1. American Academy of Dermatology - Bullous Pemphigoid guidance — Link
  2. British Association of Dermatologists - Bullous Pemphigoid guidelines — Link